Lact-pyrondridin and its pharmaceutical composition

A pyronaridine meter and drug technology, which is applied in the direction of drug combination, non-active ingredients of polymer compounds, anti-infective drugs, etc., can solve the problems of low bioavailability, economic burden, low oral bioavailability, etc.

Inactive Publication Date: 2009-09-30
CHONGQING TONGTIAN PHARMA
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the oral bioavailability of pyronaridine is low, about 40% (see, for example, Chen Xinqian, et al., New Pharmacology, 15th Edition, Beijing, People's Medical Publishing House, 2003: 140)
Such low bioavailability drugs will be a huge economic burden for developing countries

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lact-pyrondridin and its pharmaceutical composition
  • Lact-pyrondridin and its pharmaceutical composition
  • Lact-pyrondridin and its pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0078] Compound Preparation Example 1: Preparation of Pyrenaridine Lactate

[0079] Precisely take 0.1 mol of pyronaridine, 1 liter of 95% ethanol, heat to dissolve, add 0.13 mol of lactic acid, reflux for 1.5 hours, concentrate in vacuo, stand for 12-24 hours, collect the precipitate, dry to obtain pyronaridine lactic acid.

[0080] Test results: pyronaridine lactate, amorphous powder, n=1, molecular weight 608, melting point 113°C, cm -1 : 3500 (NH), 3334 (OH), 1740 (C=O); mass spectrum m / z: 518.

preparation example 2

[0081] Compound Preparation Example 2: Preparation of Pyrenaridine Lactate

[0082] Precisely take 0.1 mol of pyronaridine and 1 liter of ethyl acetate, put them in a container, heat to dissolve, add 0.13 mol of lactic acid, and reflux for 1.5 hours; concentrate in vacuo, let stand for 12-24 hours, collect crystals, dry to obtain pyronaridine lactic acid Pyridine.

[0083] Test result: pyronaridine lactate, amorphous powder, n=1, molecular weight 608, cm -1 : 3500 (NH), 3334 (OH), 1740 (C=O); mass spectrum m / z: 518.

preparation example 3

[0084] Compound Preparation Example 3: Preparation of Pyrenaridine Lactate

[0085] Precisely take 0.1 mol of pyronaridine and 1 liter of ethyl acetate, put them in a container, heat to dissolve, add 0.26 mol of lactic acid; reflux for 2 hours; concentrate in vacuo, let stand for 12-24 hours, collect the precipitate, and dry to obtain pyronaridine lactate Pyridine.

[0086] Test result: pyronaridine lactate, viscous, n=2, molecular weight 698, cm -1 : 3500 (NH), 3334 (OH), 1740 (C=O); mass spectrum m / z: 518.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
Login to view more

Abstract

The invention provides lact-pyrondridin and its pharmaceutical composition, more specificly, the invention provides compound of formula I, wherein n is 1 to 4, or its solvate, crystal type, amorphous material. The invention also provides a pharmaceutical composition comprising compound of formula I, compound pharmaceutical combination comprising compound of formula I and arteannuin analog, medicine kit product comprising compound of formula I and arteannuin analog, and uses of the compound of formula I, pharmaceutical composition or compound pharmaceutical combination in preparing medicine for prevention and / or cure for the malaria. The compound of formula I possesses higher bioavailability and synergistic effect with arteannuin analog.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to a new pyronaridine salt. Specifically, the present invention relates to the lactate of pyronaridine, and the present invention also relates to a pharmaceutical composition comprising the lactate, a compound drug combination comprising the lactate and an artemisinin analog, including the lactate A medicine box product with artemisinin analogues, and the use of the lactate salt, pharmaceutical composition or compound drug combination in the preparation of medicines for preventing and / or treating malaria. Background technique [0002] Malaria is the most widespread tropical parasitic infectious disease with the highest morbidity and mortality in the world. According to the statistics of the World Health Organization (WHO), malaria is prevalent in more than 90 countries and regions, and the number of clinical cases reaches 300-500 million Person-time / year, 1.5 to 2.7 million people di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D471/04C07C59/08A61K31/4745A61K31/366A61K31/357A61K47/40A61P33/06
CPCC07D471/04A61P33/06Y02A50/30
Inventor 郑一敏周慧胥修英韩玉梅
Owner CHONGQING TONGTIAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap